4 weeks. The steady-state RBC folate concentrations were significantly different between HbSS and HbSC patients (P ϭ 0.016), and between HbSS patients and HbAA controls (P Ͻ0.0001), as determined by the Student t-test. Our observation is consistent with the establishment of RBC folate concentrations during hemopoiesis and a subsequent decrease during circulation, causing higher RBC folate concentrations in young circulating RBCs (2, 3 ).
4 weeks. The steady-state RBC folate concentrations were significantly different between HbSS and HbSC patients (P ϭ 0.016), and between HbSS patients and HbAA controls (P Ͻ0.0001), as determined by the Student t-test. Our observation is consistent with the establishment of RBC folate concentrations during hemopoiesis and a subsequent decrease during circulation, causing higher RBC folate concentrations in young circulating RBCs (2, 3 ) .
At steady state, subjects with HbSS, HbSC, and HbAA have apparent RBC half-lives of 5-10, 12-25, and 25-40 days, respectively (4 ) . The association with RBC turnover became apparent by an inverse relationship between steady-state RBC folate and Hb (Fig. 1, top) and a positive relationship between steady-state RBC folate and the sum of the RBC polyamines spermidine and spermine (Fig. 1, bottom) . The latter is a sensitive marker of mean RBC age, with young RBCs having the highest concentrations (4 ).
One may argue that the use of special cutoff values, e.g., those derived from HbSS and HbSC patients with optimal folate status, can circumvent the confounding dependence of RBC folate on RBC age. Special cutoff values may, however, cause low sensitivity because of the heterogeneity of RBC turnover in patients classified according to Hb types and the occasional occurrence of hemolytic and vaso-occlusive crises in SCD. For example, patients with concomitant hereditary persistent HbF will have lower RBC turnover. In addition, the frequently occurring concomitant ␣-thalassemia also modifies disease activity. It might, therefore, be better to use serum folate and preferably homocysteine for the establishment of folate status, although the latter also depends on vitamins B 12 and B 6 , and other factors. Our proposal is in accordance with a previous recommendation to use fructosamine and not glycohemoglobin or HbX 1c in SCD patients because, in contrast to HbX 1c and glycohemoglobin, fructosamine is not confounded by dependence on RBC turnover rate (4 ). 
Increases of Creatine Kinase MB and Cardiac Troponin T in Serum of a Patient with Uterine Leiomyosarcoma
To the Editor: A 64-year-old woman with peripheral vascular disease and coronary artery disease presented to a university hospital with a 2-week-old hip fracture, which was operated on the day after the admission. She had had a myocardial infarction 2 years earlier, and the systolic function was slightly reduced. After the operation, the patient had intermittent chest pain. Nitroglycerin had no effect on the pain. The electrocardiogram was unchanged. Cardiac enzymes were followed (Table 1 ). Unstable angina pectoris was initially suspected, and the patient was treated accordingly.
Because of abdominal pain and vaginal bleeding, she underwent a fractional abrasion, which revealed a uterine tumor and intrauterine pus. She had fever and increased C-reactive protein (352 mg/L) and was treated with antibiotics. A uterine cancer and an abdominal abscess were suspected, and the gynecologist wanted to operate as soon as possible.
Cardiac enzymes were increased (Table 1 ). There was no biochemical evidence of hepatic or renal failure, and no clinical or x-ray signs of congestive heart failure. The chest pain episodes were atypical of angina pectoris, and serum troponin T (TnT) and creatine kinase MB (CK-MB) were stable during the observation period ( Table 1) . Cardiac troponin T (cTnT) was analyzed with the thirdgeneration TnT test (Troponin T STAT) on an Elecsys 2010 immunoassay analyzer. The third-generation TnT test uses the same monoclonal antibodies (M11.7 and M7) as the second-generation test but is standardized with human recombinant cTnT instead of bovine cTnT (Roche Diagnostics). CK-MB was measured with an assay that uses two monoclonal antibodies (CKMB STAT) on an Elecsys 2010 analyzer (Roche Diagnostics) by electrochemiluminescence immunoassay.
Would a leiomyosarcoma increase cardiac enzymes in serum? A Medline search of leiomyosarcoma and troponin revealed no such reports. Recently, a metastatic alveolar rhabdomyosarcoma was reported to increase CK-MB and TnT in serum (1, 2 ) . Increased CK-MB was reported in a patient with rhabdomyosarcoma (3 ), although that patient had received cytotoxic chemotherapy, which might have increased CK-MB in serum. Importantly, our patient received no chemotherapy. CK-MB and CK-BB have been reported in the homogenate of a lung tumor (4 ) .
In our patient, the need for surgery was urgent, and considering the atypical chest pain, the unchanged electrocardiogram, and the sustained enzyme increases, it was felt likely that the increases in the cardiac enzymes were secondary to tumor expression of CK-MB and TnT, despite the lack of such reports previously. A hysterectomy was performed, and a tubo-ovarian abscess was removed. The pathology report confirmed a low-grade leiomyosarcoma. The day after the surgery, CK-MB and TnT were within the reference limits (Table 1). The patient was discharged after another week.
In summary, this is the first report suggesting that malignant leiomyosarcoma may be associated with increased CK-MB and TnT.
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Failure of Assay to Identify Low Cobalamin Concentrations
To the Editor: We wish to report a serious problem in the ADVIA:Centaur ® chemiluminescence assay for cobalamin (Bayer Diagnostics; formerly the ACS:Centaur ® assay, Chiron Diagnostics). The problem is urgent for two reasons: (a) our findings suggest that many cobalamin-deficient patients are being missed; and (b) the assay is used by increasing numbers of laboratories, which some time ago abandoned radioisotopic methods and were recently faced with the withdrawal of widely used assays by Abbott Laboratories.
Several months after our hospital's clinical laboratory introduced the Centaur assay, we noted that the number of subnormal results being reported had declined from ϳ15-20 to 4 -5 per month. When we reassayed two serum specimens that had given subnormal cobalamin results with the Abbott IMx ® method earlier and had been stored at Ϫ20°C, the results obtained with the Centaur method were within reference values.
As a result of these observations, we selected 33 sera from our research collection of specimens that had been assayed with our radioisotope dilution assay (RIDA) and stored at Ϫ20°C. The methodologic details of the RIDA, which uses pure intrinsic factor as the binding protein, have been published (1 ), with a reference interval of 140 -750 pmol/L established in 332 subjects (2 ) .
Twenty-two of the 33 sera that we selected for testing had low cobalamin concentrations by RIDA and were from well-characterized patients with cobalamin deficiency. As established by clinical and metabolic evaluation by one of us (R.C.), pernicious anemia or ileal malabsorption (diagnosed by Schilling tests and, where appropriate, by serum antiintrinsic factor antibody and serum gastrin testing) was responsible for the deficiency in 13 of the 22 cases; all 13 patients had documented megaloblastic anemia and/or neurologic symptoms. The other 9 cobalamindeficient sera were from patients with mild preclinical deficiency [see Carmel (3 ) for background], which had been documented by metabolic 
